CN108126026A - 虫草芪参胶囊的制备方法 - Google Patents
虫草芪参胶囊的制备方法 Download PDFInfo
- Publication number
- CN108126026A CN108126026A CN201611089378.9A CN201611089378A CN108126026A CN 108126026 A CN108126026 A CN 108126026A CN 201611089378 A CN201611089378 A CN 201611089378A CN 108126026 A CN108126026 A CN 108126026A
- Authority
- CN
- China
- Prior art keywords
- extract
- prepare
- filtrate
- cordyceps sinensis
- ethyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 241001248610 Ophiocordyceps sinensis Species 0.000 title claims abstract description 22
- 239000002775 capsule Substances 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims abstract description 12
- 240000008866 Ziziphus nummularia Species 0.000 claims abstract description 11
- 229940107666 astragalus root Drugs 0.000 claims abstract description 11
- 229940119485 safflower extract Drugs 0.000 claims abstract description 11
- 235000017276 Salvia Nutrition 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 239000000706 filtrate Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 235000019441 ethanol Nutrition 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 12
- 241001072909 Salvia Species 0.000 claims description 8
- 239000009636 Huang Qi Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 244000020518 Carthamus tinctorius Species 0.000 claims description 6
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000002137 ultrasound extraction Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 6
- 230000000857 drug effect Effects 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 5
- 241001061264 Astragalus Species 0.000 description 4
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 235000006533 astragalus Nutrition 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 210000004233 talus Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010001580 Albuminuria Diseases 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000022461 Glomerular disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 231100000852 glomerular disease Toxicity 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010011730 Cylindruria Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010050791 Leukocyturia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000008718 Pyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- -1 glycosides compound Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中草药提取技术领域,公开了虫草芪参胶囊的制备方法,其包括如下步骤:步骤1)制备冬虫夏草细粉,步骤2)制备黄芪提取物,步骤3)制备丹参提取物,4)制备红花提取物,步骤5)制备酸枣仁提取物,步骤6)混匀、粉碎以及干燥。本发明制备工艺简单可行,对不同的中药成分采用不同技术进行处理,提高了各原料的有效成分,增加了药效,减少了原料浪费。
Description
技术领域
本发明属于中草药提取技术领域,具体的,涉及虫草芪参胶囊的制备方法。
背景技术
肾病一直以来未受到大家的足够重视,但当其演变成肾功能衰竭-尿毒症时,其危害不亚于癌症,且由于不规范治疗、滥用药物以及不良的生活方式导致我国的肾病发病率也连年上升。慢性肾炎又称慢性肾小球肾炎是一组病因多样、病理形态不同而临床表现相似的肾小球疾病,是一种以肾脏病变为主的全身性疾病,临床以水肿、蛋白尿为主症,伴有不同程度的肾功能减退,常反复发作,迁延难愈,后期可出现贫血、视网膜病变及尿毒症,甚至危及生命。其主要表现有:(1)水肿;(2)高血压;(3)肾区疼痛及肾绞痛;(4)尿路刺激征(即尿急、尿痛、尿频);(5)排尿异常(包括尿量减少、蛋白尿、血尿、管型尿、白细胞尿、脓尿和菌尿、肾功能试验阳性等。据数组不完全资料统计,慢性肾小球疾病在我国的患病率约1~2%。近年来,肾脏病发病率亦有不断升高的趋势。
虫草芪参胶囊是一种有效治疗慢性肾炎的药物,其原料成分相对简单,而且效果好,毒副作用小,备受患者青睐。申请人在制药过程中发现,该药物制备方法比较单一,对多种原料采用相同提取工艺,存在有效成分流失的缺陷,而且虫草芪参胶囊每次需要服用4粒,每天三次,服药量过大,部分病人很难接受,容易出现排斥情绪。如何通过改进工艺,来最大限度的利用原料,提高药效,是我们需要研究的问题。
目前市售的黄芪注射液一般采用水提醇沉的方法制备,注射剂中有效成分为黄芪皂苷,不含黄芪多糖或含量极少,而黄芪多糖也是黄芪的有效成分,具有增强免疫力、抗病毒、抗肿瘤、抗辐射、抗应激、抗氧化等作用;并且醇沉法制得的注射液稳定性较差,使其保存过程中易析出沉淀,影响使用。
发明内容
为了克服现有技术的缺陷,本发明提出虫草芪参胶囊的制备方法,该工艺简单可行、最大限度提取了原料的有效成分,提高了药效,减少了药物服用量。
本发明是通过如下技术方案来实现的:
虫草芪参胶囊的制备方法,其包括如下步骤:步骤1)制备冬虫夏草细粉,步骤2)制备黄芪提取物,步骤3)制备丹参提取物,4)制备红花提取物,步骤5)制备酸枣仁提取物,步骤6)混匀、粉碎以及干燥。
具体地,所述步骤1)制备冬虫夏草细粉,包括如下步骤:取冬虫夏草140g,粉碎成细粉。
具体地,所述步骤2)制备黄芪提取物,包括如下步骤:取黄芪1400g,粉碎,过200目筛,置于容器中,添加两倍重量的85%(v/v)的乙醇,300rpm搅拌提取,提取过程中控制微波功率为500W,提取时间为60-90min;然后置于4℃放置12h,过滤,滤渣备用;滤液减压蒸发回收乙醇,并浓缩滤液至密度为1.2-1.3g/ml的浸膏A;
将滤渣加两倍重量的水,搅拌均匀,然后加入0.5wt%的中性蛋白酶 (20万U/g),在37℃酶解120min,然后煮沸5min,然后加入占滤渣两倍重量的无水乙醇,300rpm搅拌5min,然后静置12h,去除上清液,收集沉淀,加水溶解,-20℃放置12h,然后3000rpm离心,过滤去除沉淀,将滤液减压浓缩至密度为1.2-1.3g/ml的浸膏B;合并浸膏A和浸膏B得到黄芪提取物。
具体地,所述步骤3)制备丹参提取物,包括如下步骤:取丹参560g,粉碎,过200目筛,然后铺成3mm厚度的平层,置于紫外线下照射10-15min,收集粉末置于容器中,添加两倍重量的水,300rpm搅拌提取,提取过程中控制微波功率为700W,提取时间为20-30min;过滤,收集滤液,浓缩成1.2-1.3g/ml的浸膏,即得丹参提取物。
具体地,所述4)制备红花提取物,包括如下步骤:取红花560g,投入超声提取罐,加入三倍重量的75%(体积份数)的乙醇,控制提取温度为40-50℃,以频率50KHz超声提取30-50min,过滤,收集滤液,浓缩成1.2-1.3g/ml的浸膏,即得红花提取物;
具体地,所述步骤5)制备酸枣仁提取物,包括如下步骤:取酸枣仁280g,加水煎煮两次,第一次加8倍重量的水,煎煮2小时,过滤后得到滤液和药渣;往药渣添加5倍重量的水,煎煮1.5小时,过滤得滤液;合并上述两次的滤液,浓缩成密度为1.1g/ml的清膏,冷却,添加乙醇使含醇量达70%(体积分数),静置24小时,滤过,取上清液,减压回收乙醇,浓缩至密度为1.3-1.4g/ml的浸膏,即得酸枣仁提取物;
具体地,所述步骤6)混匀、粉碎以及干燥:将步骤2)所得黄芪提取物,步骤3)所得丹参提取物,步骤4)所得红花提取物,步骤5)所得酸枣仁提取物,混匀,60-70℃烘干,然后粉碎,加入步骤1)所得细粉,混匀,干燥,制成胶囊,即得。
本发明相对于现有技术具有如下的优点及效果:
本发明制备工艺简单可行,对不同的中药成分采用不同技术进行处理,提高了各原料的有效成分,增加了药效,减少了原料浪费;丹参提取时,采用煎煮的方式,容易导致酚酸以及酮类物质的分解,本发明工艺采用微波水提的方式,避免了上述缺陷;较小的粒径能够提高黄芪有效组分的浸出率,配合微波醇提等获得苷类化合物以及多糖类,避免了成分的流失;本发明丹参提取工艺采用合适强度的紫外线,提高了有效成分的溶出度,同时采用微波辅助水提,时间短,提高了提取效率,降低了能耗;红花中的绿原酸等酸类物质、酚类有效物质不易采用煎煮的方式,本发明采用醇提,保留了有效成分;本发明制备的胶囊制剂有效成分高,效果好,动物实验提示其效果优于现有的胶囊制剂,可用于进一步的临床研究。
具体实施方式
为了使本技术领域的人员更好地理解本申请中的技术方案,下面将结合本申请具体实施例,对本发明进行更加清楚、完整地描述,显然,所描述的实施例仅仅是本申请一部分实施例,而不是全部的实施例。基于本申请中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都应当属于本发明保护的范围。
实施例1
虫草芪参胶囊的制备方法,其包括如下步骤:
1)取冬虫夏草140g,粉碎成细粉;
2)取黄芪1400g,粉碎,过200目筛,置于容器中,添加两倍重量的85%(v/v)的乙醇,300rpm搅拌提取,提取过程中控制微波功率为500W,提取时间为60-90min;然后置于4℃放置12h,过滤,滤渣备用;滤液减压蒸发回收乙醇,并浓缩滤液至密度为1.2g/ml的浸膏A;采用高效液相色谱法测试提取液中黄芪甲苷含量为1.29mg/ml;
将滤渣加两倍重量的水,搅拌均匀,然后加入0.5wt%的中性蛋白酶 (20万U/g),在37℃酶解120min,然后煮沸5min,然后加入占滤渣两倍重量的无水乙醇,300rpm搅拌5min,然后静置12h,去除上清液,收集沉淀,加水溶解,-20℃放置12h,然后3000rpm离心,过滤去除沉淀,将滤液减压浓缩至密度为1.2g/ml的浸膏B;合并浸膏A和浸膏B得到黄芪提取物;采用凝胶色谱法测得浸膏B中黄芪多糖分子量多分布于20000~40000,占总糖的70%以上;
3)取丹参560g,粉碎,过200目筛,然后铺成3mm厚度的平层,置于紫外线下照射15min,收集粉末置于容器中,添加两倍重量的水,300rpm搅拌提取,提取过程中控制微波功率为700W,提取时间为20min;过滤,收集滤液,浓缩成1.2g/ml的浸膏,即得丹参提取物;所述紫外线强度为3000uW/cm2;
4) 取红花560g,投入超声提取罐,加入三倍重量的75%(体积份数)的乙醇,控制提取温度为50℃,以频率50KHz超声提取30min,过滤,收集滤液,浓缩成1.2g/ml的浸膏,即得红花提取物;
5)取酸枣仁280g,加水煎煮两次,第一次加8倍重量的水,煎煮2小时,过滤后得到滤液和药渣;往药渣添加5倍重量的水,煎煮1.5小时,过滤得滤液;合并上述两次的滤液,浓缩成密度为1.1g/ml的清膏,冷却,添加乙醇使含醇量达70%(体积分数),静置24小时,滤过,取上清液,减压回收乙醇,浓缩至密度为1.3g/ml的浸膏,即得酸枣仁提取物;
6)将步骤2)所得黄芪提取物,步骤3)所得丹参提取物,步骤4)所得红花提取物,步骤5)所得酸枣仁提取物,混匀,60℃烘干,然后粉碎,加入步骤1)所得细粉,混匀,干燥制成1000粒。
用法用量:口服,一次2-3粒,0.45g/粒,一日3次。
对照例1
一种用于治疗慢性肾炎的虫草芪参胶囊,其由下述重量的原料制备而得:冬虫夏草140g、黄芪 1400g、丹参 560g、红花 560g、酸枣仁280g
所述虫草芪参胶囊的制备方法为:按照重量称取原料药备用
(1)取冬虫夏草粉碎成细粉;
(2)取黄芪、丹参、红花、酸枣仁加水煎煮两次,第一次加10倍量水,煎煮2小时,过滤后得到滤液和药渣;
(3)在步骤(2)中所得到的药渣添加8倍量水,煎煮1.5小时,过滤得滤液;
(4)合并步骤(2)和步骤(3)的滤液,浓缩成相对密度为1.16-1.18(50℃)的清膏,冷却,添加乙醇使含醇量达70%(体积分数),静置24小时,滤过,取上清液,减压回收乙醇,浓缩至密度为1.38-1.40g/ml(50℃)的干浸膏,粉碎,加入步骤(1)制备的细粉混匀,干燥制成1000粒。
用法用量:口服,一次4粒,0.45g/粒,一日3次。
实施例2
动物毒性试验
健康昆明品系小鼠40只,雌雄各半,体重为18.9±1.7g, 将40只小鼠随机分为两组,每组雌雄各半,其中20只做为对照组,灌以常水;另外20只小鼠给予实施例1工艺制备的制剂,剂量为100mg/kg,每天三次,应用小鼠进行毒性实验表明:与对照组比较,给药后小鼠未见明显差异,实验连续观察两周,小鼠全身状况、摄食、饮水、体重增长均正常。给药当天及给药后两周内,未见动物死亡,提示该药毒性低,临床用药安全。
实施例3
药效对比试验
动物:SD雄性大鼠60只,体重223±17g,健康清洁级,本公司实验动物中心饲养。
分组处理:60只SD雄性大鼠,根据体重无显著差异随机选取15只为空白对照组,其余45只进行阿霉素肾病模型制备。将模型大鼠根随机分为模型对照组(灌胃生理盐水,剂量100mg/kg)、实施例1组(灌胃实施例1的制剂,剂量100mg/kg)、对照例1组(灌胃对照例1的制剂,剂量100mg/kg),每组15只。每日灌胃一次,连续一月。各组大鼠分别于试验开始时和结束时留取24h尿量以测量24h尿蛋白定量(磺柳酸法)。
观察指标:包括大鼠饮食量、体毛、大便、精神状态及体重、水肿等情况。
结果:模型对照组大鼠精神较差,食量减少,体重减轻,体毛蓬松,自第三周开始水肿明显。实施例1组和对照例1组大鼠精神较好,食量较多,体重重于模型对照组,水肿较轻,而实施例1组体重、精神、食量、水肿状况好于对照例1组。各组大鼠尿蛋白定量动态变化比较见表1所示。
表1
组别 | 开始时间检测结果 | 结束时间检测结果 |
空白对照组 | 23.78±4.61 | 24.47±5.28 |
模型对照组 | 237.63±53.19 | 381.94±71.62 |
实施例1组 | 246.26±64.36 | 194.72±53.27 |
对照例1组 | 229.54±59.44 | 272.61±64.58 |
结论:本发明实施例1的制剂对小鼠慢性肾炎有较好的治疗作用,效果显著优于对照例1(本公司在售产品)。
最后,还需要注意的是,以上列举的仅是本发明的若干个具体实施例。显然,本发明不限于以上实施例,还可以有许多变形。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。
Claims (7)
1.虫草芪参胶囊的制备方法,其包括如下步骤:步骤1)制备冬虫夏草细粉,步骤2)制备黄芪提取物,步骤3)制备丹参提取物,4)制备红花提取物,步骤5)制备酸枣仁提取物,步骤6)混匀、粉碎以及干燥。
2.根据权利要求1所述的制备工艺,其特征在于,所述步骤1)制备冬虫夏草细粉,包括如下步骤:取冬虫夏草140g,粉碎成细粉。
3.根据权利要求1所述的制备工艺,其特征在于,所述步骤2)制备黄芪提取物,包括如下步骤:取黄芪1400g,粉碎,过200目筛,置于容器中,添加两倍重量的85%(v/v)的乙醇,300rpm搅拌提取,提取过程中控制微波功率为500W,提取时间为60-90min;然后置于4℃放置12h,过滤,滤渣备用;滤液减压蒸发回收乙醇,并浓缩滤液至密度为1.2-1.3g/ml的浸膏A;
将滤渣加两倍重量的水,搅拌均匀,然后加入0.5wt%的中性蛋白酶,在37℃酶解120min,然后煮沸5min,然后加入占滤渣两倍重量的无水乙醇,300rpm搅拌5min,然后静置12h,去除上清液,收集沉淀,加水溶解,-20℃放置12h,然后3000rpm离心,过滤去除沉淀,将滤液减压浓缩至密度为1.2-1.3g/ml的浸膏B;合并浸膏A和浸膏B得到黄芪提取物。
4.根据权利要求1所述的制备工艺,其特征在于,所述步骤3)制备丹参提取物,包括如下步骤:取丹参560g,粉碎,过200目筛,然后铺成3mm厚度的平层,置于紫外线下照射10-15min,收集粉末置于容器中,添加两倍重量的水,300rpm搅拌提取,提取过程中控制微波功率为700W,提取时间为20-30min;过滤,收集滤液,浓缩成1.2-1.3g/ml的浸膏,即得丹参提取物。
5.根据权利要求1所述的制备工艺,其特征在于,所述4)制备红花提取物,包括如下步骤:取红花560g,投入超声提取罐,加入三倍重量的75%(体积份数)的乙醇,控制提取温度为40-50℃,以频率50KHz超声提取30-50min,过滤,收集滤液,浓缩成1.2-1.3g/ml的浸膏,即得红花提取物。
6.根据权利要求1所述的制备工艺,其特征在于,所述步骤5)制备酸枣仁提取物,包括如下步骤:取酸枣仁280g,加水煎煮两次,第一次加8倍重量的水,煎煮2小时,过滤后得到滤液和药渣;往药渣添加5倍重量的水,煎煮1.5小时,过滤得滤液;合并上述两次的滤液,浓缩成密度为1.1g/ml的清膏,冷却,添加乙醇使含醇量达70%(体积分数),静置24小时,滤过,取上清液,减压回收乙醇,浓缩至密度为1.3-1.4g/ml的浸膏,即得酸枣仁提取物。
7.根据权利要求1-6任其一所述的制备工艺,其特征在于,所述步骤6)混匀、粉碎以及干燥:将步骤2)所得黄芪提取物,步骤3)所得丹参提取物,步骤4)所得红花提取物,步骤5)所得酸枣仁提取物,混匀,60-70℃烘干,然后粉碎,加入步骤1)所得细粉,混匀,干燥,制成胶囊,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611089378.9A CN108126026B (zh) | 2016-12-01 | 2016-12-01 | 虫草芪参胶囊的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611089378.9A CN108126026B (zh) | 2016-12-01 | 2016-12-01 | 虫草芪参胶囊的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108126026A true CN108126026A (zh) | 2018-06-08 |
CN108126026B CN108126026B (zh) | 2021-01-08 |
Family
ID=62387622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611089378.9A Active CN108126026B (zh) | 2016-12-01 | 2016-12-01 | 虫草芪参胶囊的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108126026B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106491747A (zh) * | 2016-12-27 | 2017-03-15 | 翔宇药业股份有限公司 | 虫草芪参胶囊的制备及质量标准检测方法 |
CN106728079A (zh) * | 2016-12-27 | 2017-05-31 | 翔宇药业股份有限公司 | 虫草芪参胶囊制剂的生产方法 |
CN106728080A (zh) * | 2016-12-27 | 2017-05-31 | 翔宇药业股份有限公司 | 一种治疗慢性肾炎的复方药物的制备工艺 |
CN110201117A (zh) * | 2019-06-10 | 2019-09-06 | 黑龙江天翼药业有限公司 | 心舒宝胶囊及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103638136A (zh) * | 2013-12-22 | 2014-03-19 | 林凡友 | 虫草芪参胶囊 |
CN103864617A (zh) * | 2012-12-07 | 2014-06-18 | 廉吉芳 | 一种从金银花中提取绿原酸的方法 |
CN104558224A (zh) * | 2014-12-08 | 2015-04-29 | 向华 | 从黄芪废渣中制备黄芪多糖和保水凝胶的方法 |
CN105412209A (zh) * | 2015-12-08 | 2016-03-23 | 广东艾希德药业有限公司 | 一种黄芪提取物及其制备方法与应用 |
-
2016
- 2016-12-01 CN CN201611089378.9A patent/CN108126026B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103864617A (zh) * | 2012-12-07 | 2014-06-18 | 廉吉芳 | 一种从金银花中提取绿原酸的方法 |
CN103638136A (zh) * | 2013-12-22 | 2014-03-19 | 林凡友 | 虫草芪参胶囊 |
CN104558224A (zh) * | 2014-12-08 | 2015-04-29 | 向华 | 从黄芪废渣中制备黄芪多糖和保水凝胶的方法 |
CN105412209A (zh) * | 2015-12-08 | 2016-03-23 | 广东艾希德药业有限公司 | 一种黄芪提取物及其制备方法与应用 |
Non-Patent Citations (6)
Title |
---|
JIAN SHI ET.AL: "Study of pharmacokinetic profiles and characteristics of active components and their metabolites in rat plasma following oral administration of the water extract of Astragali radix using UPLC–MS/MS", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
孔令义: "《天然药物化学》", 31 August 2015, 中国医药科技出版社 * |
宋丽雅等: "《化妆品植物功效添加剂的研究与开发》", 30 September 2011, 中国轻工业出版社 * |
宗晓菲等: "不同溶剂和提取方法对红花提取物抗氧化活性的影响", 《贵州农业科学》 * |
张兆旺: "《中药药剂学》", 31 March 2007, 中国中医药出版社 * |
李江英等: "《现代中药制剂理论与实践》", 30 September 2016, 陕西科学技术出版社 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106491747A (zh) * | 2016-12-27 | 2017-03-15 | 翔宇药业股份有限公司 | 虫草芪参胶囊的制备及质量标准检测方法 |
CN106728079A (zh) * | 2016-12-27 | 2017-05-31 | 翔宇药业股份有限公司 | 虫草芪参胶囊制剂的生产方法 |
CN106728080A (zh) * | 2016-12-27 | 2017-05-31 | 翔宇药业股份有限公司 | 一种治疗慢性肾炎的复方药物的制备工艺 |
CN106728080B (zh) * | 2016-12-27 | 2020-02-21 | 翔宇药业股份有限公司 | 一种治疗慢性肾炎的复方药物的制备工艺 |
CN106728079B (zh) * | 2016-12-27 | 2020-02-21 | 翔宇药业股份有限公司 | 虫草芪参胶囊制剂的生产方法 |
CN106491747B (zh) * | 2016-12-27 | 2020-03-24 | 翔宇药业股份有限公司 | 虫草芪参胶囊的制备及质量标准检测方法 |
CN110201117A (zh) * | 2019-06-10 | 2019-09-06 | 黑龙江天翼药业有限公司 | 心舒宝胶囊及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108126026B (zh) | 2021-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108126026A (zh) | 虫草芪参胶囊的制备方法 | |
CN1931261B (zh) | 一种降压降脂胶囊及其制备方法 | |
CN110870889A (zh) | 一种中药组合物及其制备方法和应用 | |
CN101485870A (zh) | 一种健胃驱虫药 | |
CN101264215A (zh) | 一种治疗急慢性痛风性关节炎的药物组合及其制备方法 | |
CN102657834A (zh) | 一种治疗酒精中毒的中药组合物及其制备工艺 | |
CN102319357B (zh) | 一种降脂灵分散片及其制备工艺 | |
CN106279462A (zh) | 黄芪多糖的提取方法及兽用黄芪多糖口服液的制备方法 | |
CN104274765A (zh) | 一种对肿瘤化疗具有减毒增效的中药组合物及其制备方法 | |
CN101347605B (zh) | 一种用于治疗痛风的中药组合物及其制备方法和用途 | |
CN104474135B (zh) | 一种对化学性肝损伤具有辅助保护功能的药物组合物 | |
CN108686113A (zh) | 一种缓解三高症状的组合物及其制备方法 | |
CN101167863B (zh) | 一种治疗糖尿病肾病的中成药及其制备方法 | |
CN102579980A (zh) | 一种治疗肝胆系统结石的药物 | |
CN106729406A (zh) | 经前安制剂的制备方法 | |
CN108126052A (zh) | 一种颐神颗粒的制备工艺 | |
CN108126025A (zh) | 清浊益肾胶囊的制备工艺 | |
CN103007112B (zh) | 一种预防和治疗婴幼儿湿疹的中药组合物及其制备方法 | |
CN106728081A (zh) | 清浊益肾胶囊的制备及质量标准检验方法 | |
CN103638149B (zh) | 一种治疗直肠癌的中药组合物 | |
CN106728080B (zh) | 一种治疗慢性肾炎的复方药物的制备工艺 | |
CN106728079B (zh) | 虫草芪参胶囊制剂的生产方法 | |
CN106491747B (zh) | 虫草芪参胶囊的制备及质量标准检测方法 | |
CN100475248C (zh) | 一种治疗子宫出血的药物及其制备工艺 | |
CN110101694A (zh) | 穿心莲内酯的应用及穿心莲内酯肛门栓的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201204 Address after: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Shandong, China Applicant after: XIANGYU PHARMACEUTICAL Co.,Ltd. Address before: 276023 Xiangyu pharmaceutical Limited by Share Ltd, No. 30 Hangzhou Road, Linyi economic and Technological Development Zone, Shandong Applicant before: Lin Fanyou |
|
GR01 | Patent grant | ||
GR01 | Patent grant |